

Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial

Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM, KEYNOTE-716 Investigators.

Lancet

2022; 399(10336):1718-1729

ARTICLE IDENTIFIERS

DOI: 10.1016/S0140-6736(22)00562-1

PMID: 35367007

PMCID: not available

JOURNAL IDENTIFIERS

LCCN: sf 82002015

pISSN: 0140-6736

eISSN: 1474-547X

OCLC ID: 01755507

CONS ID: not available

US National Library of Medicine ID: 2985213R

This article was identified from a query of the SafetyLit database.